TrialFrontiers in endocrinology2021

Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study.

Rosario Pivonello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.